Article

SETD1A-dependent EME1 transcription drives PARPi sensitivity in HR deficient tumour cells

2024-06-17

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Cells deficient in DNA repair factors breast cancer susceptibility 1/2 (BRCA1/2) or ataxia-telangiectasia mutated (ATM) are sensitive to poly-ADP ribose polymerase (PARP) inhibitors. Building on our previous findings, we asked how the lysine methyltransferase SETD1A contributed to PARP inhibitor-mediated cell death and determined the mechanisms responsible. <h4>Methods</h4>...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c7a99fd6-b598-5d10-a0de-205f0789dade
DOI: 10.1101/2024.06.16.599181

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

SETD1A-dependent EME1 transcription drives PARPi sensitivity in HR deficient tumour cellsDOI 10.1101/2024.06.16.599181Read

New perspectives on epigenetic modifications and PARP inhibitor resistance in HR-deficient cancersSemantic proximity Read

Drug-gene interaction screens coupled to tumour data analyses identify the most clinically-relevant cancer vulnerabilities driving sensitivity to PARP inhibitionSemantic proximity Read

ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination-deficient cells.Semantic proximity Read

Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP InhibitorsSemantic proximity Read

A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signaturesSemantic proximity Read

The regulation loop of MARVELD1 interacting with PARP1 in DNA damage response maintains genome stability and promotes therapy resistance of cancer cellsSemantic proximity Read

DNA double-strand break repair pathway choice - from basic biology to clinical exploitationSemantic proximity Read

Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell linesSemantic proximity Read

Loss of Nuclear DNA Ligase III Reverts PARP Inhibitor Resistance in BRCA1/53BP1 Double-deficient Cells by Exposing ssDNA GapsSemantic proximity Read

Synthetic Lethality in Cancer: Mechanistic and Therapeutic Insights into PARP Inhibitors, BRCA Mutations, and Homologous Recombination Deficiency (HRD)Semantic proximity Read

Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategiesSemantic proximity Read

Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1/2 and RAD51Semantic proximity Read